DOI QR코드

DOI QR Code

Significance of ABO-Rh Blood Groups in Response and Prognosis in Breast Cancer Patients Treated with Radiotherapy and Chemotherapy

  • 발행 : 2014.05.15

초록

Background: To evaluate whether ABO-Rh blood groups have significance in the treatment response and prognosis in patients with non-metastatic breast cancer. Materials and Methods: We retrospectively evaluated files of 335 patients with breast cancer who were treated between 2005 and 2010. Demographic data, clinic-pathological findings, treatments employed, treatment response, and overall and disease-free survivals were reviewed. Relationships between clinic-pathological findings and blood groups were evaluated. Results: 329 women and 6 men were included to the study. Mean age at diagnosis was 55.2 years (range: 26-86). Of the cases, 95% received chemotherapy while 70% were given radiotherapy and 60.9% adjuvant hormone therapy after surgery. Some 63.0% were A blood group, 17.6% O, 14.3% B and 5.1% AB. In addition, 82.0% of the cases were Rh-positive. Mean follow-up was 24.5 months. Median overall and progression-free survival times were 83.9 and 79.5 months, respectively. Overall and disease-free survival times were found to be higher in patients with A and O blood groups (p<0.05). However rates did not differ with the Rh-positive group (p=0.226). In univariate and multivariate analyses, ABO blood groups were identified as factors that had significant effects on overall and disease-survival times (p=0.011 and p=0.002). Conclusions: It was seen that overall and disease-free survival times were higher in breast cancer patients with A and O blood groups when compared to those with other blood groups. It was seen that A and O blood groups had good prognostic value in patients with breast cancer.

키워드

참고문헌

  1. Aird I, Bentall HH, Mehigan JA, Roberts JA (1954). The blood groups in relation to peptic ulceration and carcinoma of colon, rectum, breast, and bronchus; an association between the ABO groups and peptic ulceration. Br Med J, 2, 315-21. https://doi.org/10.1136/bmj.2.4883.315
  2. Anderson DE, Ferrell RE, Williams WR (1985). A linkage study of human breast cancer. Cytogenet Cell Genet, 40, 568-9.
  3. Cihan YB, Baykan H, Kavuncuoglu E, et al (2013). Relationships between skin cancer and blood groups-link between non-melanomas and ABO/Rh factors. Asian Pac J Cancer Prev, 14, 4199-203. https://doi.org/10.7314/APJCP.2013.14.7.4199
  4. Dede DS, Aksoy S, Dizdar O, et al (2010). Blood ABO groups and risk of breast cancer. Med Oncol, 27, 1433. https://doi.org/10.1007/s12032-009-9346-1
  5. Gates MA, Xu M, Chen WY, et al (2012). ABO blood group and breast cancer incidence and survival. Int J Cancer, 130, 2129-37. https://doi.org/10.1002/ijc.26220
  6. Guleria K, Singh HP, Kaur H (2005). ABO blood groups in gastrointestinal tract (GIT) and breast carcinoma patients. Anthropologist, 7, 189-92. https://doi.org/10.1080/09720073.2005.11890905
  7. Hems G (1970). Epidemiological characteristics of breast cancer in middle and late age. Br J Cancer, 24, 226-34. https://doi.org/10.1038/bjc.1970.26
  8. Holdsworth PJ, Thorogood J, Benson EA, Clayden AD (1985). Blood group as a prognostic indicator in breast cancer. Br Med J (Clin Res Ed), 290, 671-3. https://doi.org/10.1136/bmj.290.6469.671
  9. Iodice S, Maisonneuve P, Botteri E, et al (2010). ABO blood group and cancer. Eur J Cancer, 46, 3345-50. https://doi.org/10.1016/j.ejca.2010.08.009
  10. Klimant E, Glurich I, Mukesh B, Onitilo A (2011). Blood type, hormone receptor status, HER2/neu status, and survival in breast cancer: a retrospective study exploring relationships in a phenotypically well-defined cohort. Clin Med Res, 9, 111-8. https://doi.org/10.3121/cmr.2011.907
  11. Miao Su-Yu, Zhou W, Chen L, et al (2013). Influence of ABO blood group and rhesus factor on breast cancer risk: a meta-analysis of 9,665 breast cancer patients and 244,768 controls. Asia Pac J Clin Oncol, [Epub ahead of print].
  12. Mortazavi H, Hajian S, Fadavi E, et al (2014). ABO blood groups in oral cancer: a first case-control study in a defined group of Iranian patients. Asian Pac J Cancer Prev, 15, 1415-8. https://doi.org/10.7314/APJCP.2014.15.3.1415
  13. Ronco AL, Stoll M, De Stefani E, et al (2009). RH factor, family history and risk of breast cancer: a case-control study in Uruguay. Cancer Detect Prev, 32, 277-85. https://doi.org/10.1016/j.cdp.2008.12.005
  14. Sozen S, Benderli Cihan Y (2012). Tumor characteristics, treatment and survivial periods of elderly patients with breast cancer in elderly. Turkish J Geriatrics, 15, 164-70.
  15. Stamatakos M, Kontzoglou K, Safioleas P, et al (2009). Breast cancer incidence in Greek women in relation to ABO blood groups and Rh factor. Int Semin Surg Oncol, 6, 14. https://doi.org/10.1186/1477-7800-6-14
  16. Tryggvadottir L, Tulinius H, Robertson JM (1988). Familial and sporadic breast cancer cases in Iceland: a comparison related to ABO blood groups and risk of bilateral breast cancer. Int J Cancer, 42, 499-501. https://doi.org/10.1002/ijc.2910420405
  17. Unal D, Eroglu C, Kurtul N, et al (2013). ABO blood groups are not associated with treatment response and prognosis in patients with local advanced non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 3945-8. https://doi.org/10.7314/APJCP.2013.14.6.3945
  18. Urun Y, Utkan G, Yalcin., et al (2013). Lack of any relationship between ABO and Rh blood groups and clinicopathological features in patients with gastrointestinal stromal tumors: Turkish Oncology Group. Asian Pac J Cancer Prev, 14, 4129-31.
  19. Utkan G, Urun Y, Cangir AK, et al (2013). Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups. Asian Pac J Cancer Prev, 14, 249-53. https://doi.org/10.7314/APJCP.2013.14.1.249

피인용 문헌

  1. Can 9q34.2 rs633862 polymorphism predict survival in epithelial ovarian cancer? vol.5, pp.2167-8359, 2017, https://doi.org/10.7717/peerj.3946